The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the authorization of five new drugs, four of which already hold US approvals. Additionally, CHMP initiated a re-evaluation of Eli Lilly’s Alzheimer’s therapy Kisunla. These regulatory developments reflect evolving treatment options and ongoing assessments within the European pharmaceutical landscape. Notably, conditional approval was also recommended for Madrigal Pharmaceuticals’ Rezdiffra in metabolic dysfunction-associated steatohepatitis and Merck KGaA's acquired Springworks’ Ogsiveo for desmoid tumors, signaling continued progress in rare and chronic disease therapeutics.